(Q33727356)

English

Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

phase II clinical trial

0 references

darbepoetin alfa

0 references

author name string

Lee Schwartzberg

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Ronald Burkes

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Barry Mirtsching

3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Timothy Rearden

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Peter Silberstein

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Lorrin Yee

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Amy Inamoto

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Tom Lillie

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

25 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

581

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2988026

21 June 2018

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2988026

21 June 2018

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2988026

21 June 2018

A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2988026

21 June 2018

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2988026

21 June 2018

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2988026

21 June 2018

Chemotherapy-induced anemia in adults: incidence and treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2988026

21 June 2018

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-581

21 January 2018

Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-581

21 January 2018

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-10-581

21 January 2018

Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2988026

30 October 2018

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20973982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales

1 reference

https://pubmed.ncbi.nlm.nih.gov/20973982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20973982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20973982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks

1 reference

https://pubmed.ncbi.nlm.nih.gov/20973982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20973982

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-10-581

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33727356&oldid=2195702068"